Patents by Inventor Eric Steven Manas

Eric Steven Manas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS
    Publication number: 20240300965
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: April 25, 2024
    Publication date: September 12, 2024
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Emst Neipp, Vipulkumar Kantibhai Patel
  • Compounds
    Patent number: 11999746
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: June 4, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • COMPOUNDS
    Publication number: 20200055863
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 20, 2020
    Inventors: Zehong WAN, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E. Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Compounds
    Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • COMPOUNDS
    Publication number: 20190023715
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
  • Compounds
    Patent number: 10125141
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 13, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Compounds
    Publication number: 20170204109
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 20, 2017
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SWNDER, Eric Steven MANAS, Raphael Annthony RIVERO, Joseph e PERO, Christopher ERNST NEIPP, Vipuljumar Kantibhai PATEL
  • TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES
    Publication number: 20140378487
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Saiah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • Tricyclic compounds, preparation methods, and their uses
    Patent number: 8871928
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: October 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES
    Publication number: 20130178488
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 11, 2013
    Inventors: Zehong WAN, Xiaomio Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • TRPV4 antagonists
    Patent number: 8450484
    Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: May 28, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
  • TRPV4 ANTAGONISTS
    Publication number: 20110130400
    Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: July 24, 2009
    Publication date: June 2, 2011
    Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
  • Methods for the design of estrogen receptor ligands
    Patent number: 7555415
    Abstract: Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: June 30, 2009
    Assignee: Wyeth
    Inventors: Lidia Mosyak, Zhang Bao Xu, Mark Stahl, Wah-Tung Hum, William Stuart Somers, Eric Steven Manas
  • Azolylacylguanidines as ?-secretase inhibitors
    Patent number: 7488832
    Abstract: The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: February 10, 2009
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Eric Steven Manas, Lee Dalton Jennings, Frank Eldridge Lovering, Joseph Raymond Stock, William Jay Moore, John Watson Ellingboe, Jeffrey Scott Condon, Mohani Nirmala Sukhdeo, Ping Zhou, Junjun Wu, Koi Michele Morris
  • AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS
    Publication number: 20080287424
    Abstract: The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: July 15, 2008
    Publication date: November 20, 2008
    Applicant: Wyeth
    Inventors: Derek Cecil Cole, Eric Steven Manas, Lee Dalton Jennings, Frank Eldridge Lovering, Joseph Raymond Stock, William Jay Moore, John Watson Ellingboe, Jeffrey Scott Condon, Mohani Nirmala Sukhdeo, Ping Zhou, Junjun Wu, Koi Michele Morris
  • (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
    Patent number: 7250440
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure where R1, R2, R3, and R4 are as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: July 31, 2007
    Assignee: Wyeth
    Inventors: Richard Eric Mewshaw, Stephen Marc Bowen, Eric Steven Manas